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Despite significant efforts, the cellular compartment that gives rise to pancreatic ductal adenocarcinoma
(PDAC), one of the most lethal human cancers, remains obscure. In this issue of Cancer Cell, Gidekel Fried-
lander and colleagues demonstrate that under conditions of tissue damage,mutant Kras can drive previously
unsuspected insulin-positive endocrine cells into PDA.Pancreatic ductal adenocarcinoma (PDAC)
carries a dismal prognosis with a 5-year
survival rate of less than 5% and, on
average, mortality occurring within
6 months of diagnosis (Hezel et al., 2006).
The disease is generally insensitive to
chemotherapy and surgical resection is
the most effective treatment. Generic
symptoms and a lack of specific bio-
markers frustrate early detection when
surgery is possible, making the develop-
ment of diagnostic tests paramount to
increasing treatment options and efficacy.
Determining whether the capacity to serve
as a PDAC ‘‘cell of origin’’ is unique to a
specific pancreatic compartment repre-
sents a key step in guiding this search
for possible diagnostic and therapeutic
measures. A study performed by Gidekel
Friedlander et al. (2009) published in this
issue of Cancer Cell contributes to this
goal by implicating insulin-positive cells in
the adult pancreas, a previously unsus-
pected cell type, as a possible source of
PDAC.
PDAC and its suspected precursor
lesions, such as pancreatic intraepithelial
neoplasias (PanINs), possess ductal
morphology and express markers of
ductal differentiation. Therefore, PDAC
was historically believed to develop from
pancreatic duct cells. However, the recent
development of PDACmousemodels has
allowed nonductal cells to be evaluated
for their ability to give rise to PanINs and
PDAC. Thesemodels depend on amaster
role for deregulated Kras activity in PDAC
development. In humans, activatingmuta-
tions in Kras are found in nearly 100% of
PDAC and can be frequently detected in
early PanIN (Hezel et al., 2006). Seminalwork by Hingorani et al. (2003) provided
strong support to the notion that Kras
mutation represents an initiating event
in PDAC. These authors showed that
expression of mutant Kras in the multi-
potent pancreatic progenitor pool can re-
capitulate the stepwise progression of
PanINs and PDAC observed in the human
disease. Since then, more sophisticated
genetic tools have been used to test the
ability of Kras to induce PanIN and PDAC
when activated in subsets of developing
and adult pancreatic cells. In particular,
these data suggest that adult acinar cells,
the cells that produce and secrete diges-
tive enzymes into the duct network,
possess the capacity to give rise to Kras-
driven PanINs and PDAC (Habbe et al.,
2008; De La et al., 2008; Ji et al., 2009).
Furthermore,chronicpancreatitis,asignif-
icant PDAC risk factor in humans (Hezel
et al., 2006), experimentally induced in
mice through treatmentwith the cholecys-
tikinin analog caerulein, can both promote
and accelerate Kras-driven PanIN/PDAC
originated from acinar and possibly cen-
troacinar cells (a cell type located at the
junction between acini and ducts) (Fig-
ure 1; Guerra et al., 2007).
Studying the response of the pancreas
to inflammatorydamage, inparticularcaer-
ulein pancreatitis, has revealed crucial
information regarding the inherent plas-
ticity of cells in the adult pancreas and their
possible capacity to contribute to PDAC.
For example, during the early stages of
regeneration after acute pancreatitis,
acinar cells frequently assume a transient
duct-like state (Strobel et al., 2007a; Fen-
drich et al., 2008). However, in the absence
of oncogenic signals, persistent acinarCancer Cell 16,to ductal reprogramming of adult acini
appears to be tightly restricted. Evenwhen
subjected to prolonged caerulein pancrea-
titis (for example, 7–10 weeks), wild-type
acini rarely assume a fixed ductal fate,
although these ducts can resemble early
PanIN lesions (Strobel et al., 2007a). There-
fore, the ability ofmutantKras to spontane-
ously reprogram acini into ductal PanINs
suggests that the oncogene permits the
development of an otherwise generally
inaccessible differentiation state. Gidekel
Friedlander and colleagues contribute to
this growing body of evidence that adult
acini can give rise to PanINs and PDAC
by targeting mutant Kras to a subset of
acini utilizing a ProCPAERT2 driver line.
Similar to results from other models, adult
acini targeted with this Cre line did give
rise to PanINs, although infrequently.
Consistent with previous findings, chronic
chemical pancreatitis significantly acceler-
ated the development of PanINs in these
mice.
The most surprising finding by Gidekel
Friedlander and colleagues is that in-
sulin-positive endocrine cells can serve
as PDAC progenitors in the context of
Kras mutation and inflammatory damage.
The first indication for endocrine involve-
ment comes from experiments in which
a Pdx1-CreER driver line was utilized to
activate Kras in cells expressing the key
pancreatic transcription factor Pdx1,
which is found in a subset of adult acini
and ducts, butmainly restricted to specific
classes of adult endocrine cells. Whereas
Pdx1-CreER-driven recombinationwasde-
tected in both the exocrine and endocrine
compartment, PanINs were frequently
and unexpectedly found embedded inNovember 3, 2009 ª2009 Elsevier Inc. 359
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The exocrine compartment contains enzyme secreting acinar cells, duct cells, and centroacinar cells that connect acini and ducts. The cells of the endocrine
compartment are mainly located in islets of Langerhans and secrete hormones directly into the bloodstream. The insulin producing b cells (green) are the
predominant endocrine cell type. Whereas mutant Kras has been targeted to all pancreatic cell types nonspecifically during pancreatic development, Figure 1
illustrateswhich adult cell types have been specifically targetedwithmutant Kras and under what conditions their contribution to PanIN/PDAC formation has been
verified.islets, potentially indicating that mutant
Kras can reprogram endocrine cells into
PanINs. It is key to note that PanIN lesions
in these mice occurred in the absence of
caerulein administration, suggesting that
adult Pdx1-positive cells are sensitive to
reprogramming by Kras even in the
absence of tissue damage and inflamma-
tion. This is unexpected because direct
genetic evidence of in vivo endocrine to
ductalmetaplasia is lacking. In fact, lineage
tracing of insulin-positive cells inmice sub-
jected to chronic caerulein pancreatitis
showedno evidence of these cells contrib-
uting to persistent mucinous metaplastic
ductal lesions (Strobel et al., 2007b).
By utilizing a RIP-CreER (rat insulin
promoter) line to target Kras activity to
adult insulin-postive cells, Gidekel Fried-
lander and colleagues further show that
the ability of mutant Kras to exploit tissue
damage and inflammation to initiate the
PanIN toPDACsequencecanbeextended
to the endocrine compartment. Although
the mechanism of this shift in cell plasticity
is unknown, this study shows that given
a permissive state of tissue damage,
mutant Kras can drive insulin-positive cells
into an otherwise restricted duct-like state.
One theory posited by the authors is that
chronic damage amplifies an insulin-posi-
tive cell type that is sensitive to Kras
activity. Elements of embryonic pancreatic360 Cancer Cell 16, November 3, 2009 ª20development (e.g., Notch signaling, Pdx1
and Nestin expression) are reactivated in
the exocrine compartment in response to
caerulein pancreatitis (Jensen et al., 2005;
Fendrich et al., 2008). Theoretically, a
similar ‘‘dedifferentiation’’ could occur in
insulin-positive cells, rendering a cell state
that can be reprogrammed into PanINs
and PDAC.
This study has many implications on
our understanding of PDAC biology. It
demonstrates that PanINs and PDAC
can arise from nonexocrine cell types, so
it begs the question as to whether all
pancreatic cell types inherently possess
the ability to give rise to PDAC. Taken
together with recent studies targeting
mutant Kras to adult acini, the capacity
of the remaining non-b-cell endocrine
cells (such as glucagon-positive a-cells),
adult centroacinar, and duct cells to be
reprogrammed into PanIN/PDAC remains
to be specifically interrogated (Figure 1).
Furthermore, it highlights the ability of
tissue damage, specifically that charac-
teristic of chronic pancreatitis, to provide
a permissive environment for Kras-
induced reprogramming of a ‘‘PanIN/
PDAC lineage’’ from both exocrine and
endocrine cells. Determining what cell-
autonomous and extrinsic changes occur
during chronic pancreatitis that permit
this normally restricted shift in differentia-09 Elsevier Inc.tion may provide key diagnostic or thera-
peutic targets for the earliest stages of
PDAC.
Finally, this work further entrenches
mutant Kras as a master regulator of the
differentiation process that gives rise to
PDAC. In demonstrating that PDAC can
arise from cellular compartments as
distinct as the exocrine and endocrine,
this study displays a clear need to closely
dissectwhichmolecular events are critical
for Kras to first initiate the precursor state
and then drive this sensitized cell toward
PDAC. Such analysis may identify a trac-
table node for hobbling this devastating
disease, regardless of its cell of origin.
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In this issue ofCancer Cell, Zhang et
hydroxylase EglN2 inducesCyclin D
of function studies suggest the pote
apeutics.
EglN2 (also known as PHD1) is among
three known EglNs, with EglN1 (PHD2)
being key to the hydroxylation and degra-
dation of the hypoxia inducible factor 1a
(HIF-1a) (Berra et al., 2006; Epstein
et al., 2001; Kaelin and Ratcliffe, 2008).
Although the direct substrates for hydrox-
ylation by EglN2 and EglN3 are not well
understood, Zhang et al. document that
EglN2 activity positively influences the
level of Cyclin D1, independent of HIF,
in a series of in vitro experiments and
in genetically engineered mice (Zhang
et al., 2009). The authors linked EglN2 to
Cyclin D1 in breast tumorigenesis, partly
on the basis of their genetic connection
in Drosophila and the fact the EglN2 is
estrogen inducible, such that loss of
EglN2 activity diminishes breast tumori-
genesis that could be rescued by ectopic
Cyclin D1 expression.
Prolyl hydroxylases belong to the
superfamily of iron-dependent, 2-oxoglu-
tarate dioxygenases that use molecular
oxygen to hydroxylate specific prolyl resi-
dues of substrates whose functions may
be altered, or the hydroxylated substrates
are destined for degradation through
the proteasome (Kaelin and Ratcliffe,Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al.
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’ng on Cancer
cine, Johns Hopkins University School of Medic
al. reports that the iron-dependent 2-
1 levels, egging on breast tumorigene
ntial for drug-like molecules inhibitin
2008). EglNs have Km values for oxygen
that are higher than oxygen concentra-
tions inmammalian tissues, causing these
enzymes to be highly sensitive of oxygen
levels, which are naturally diminished in
areas of tissues distal from a blood vessel
or abruptly decreased by blockage of the
blood supply. With decreased oxygen
concentration, the EglNs are thought to
not only be inactivated by the lack of its
substrate oxygen but may also be
disabled by increased reactive oxygen
species (ROS) resulting from inefficient
mitochondrial respiration. ROS oxidizes
and inactivates the catalytic EglN ferrous
ion, resulting in loss of prolyl hydroxyl-
ation and stabilization of the EglNs’
substrates. Chief among the EglNs’
substrates is HIF-1a, which is a ubiquitous
transcription factor mediating cellular
genomic responses to hypoxia and a sub-
strate of EglN1 (Figure 1) (Semenza, 2007).
Zhang et al. noted on the basis of earlier
work by Frei and Edgar that the sole EglN,
Egl9, in Drosophila interacts genetically
with Cyclin D1 (Figure 1) (Frei and Edgar,
2004). Specifically, Frei and Edgar
observed that Cyclin D1 overexpression
in flies resulted in eye overgrowth, a
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oxoglutarate dioxygenase or prolyl
sis. Their observations through loss
g EglN to serve as new cancer ther-
phenotype that could be extinguished by
the concurrent loss of Egl9 function. By
examining EglN2/ mice, which are
grossly normal, Zhang et al. found that
Cyclin D1 mRNA and protein levels are
diminished in the mutant murine embry-
onic fibroblasts. They also document
hypoproliferation of mammary glands in
older EglN2 null mice reminiscent of the
more severe phenotype reported for the
Cyclin D1/ mice. These observations
in genetically engineered mice suggest
that loss of EglN2 function phenocopies
decreased Cyclin D1 activity in mammary
tissue. Intriguingly, although it is docu-
mented that hypoxia inhibits cell prolifera-
tion partly through the induction of p27
putatively downstream of HIF-1 in mam-
malian cells (Gardner et al., 2001), the
connection between EglN and Cyclin D1
in Drosophila and mice suggests a
possible alternative pathway to inhibit
cell proliferation when oxygen is lacking.
In this regard, EglN could play a direct
role in regulating the cell cycle by sup-
pressing a putative suppressor of Cyclin
D1 (Figure 1).
Cyclin D1 promotes the phosphoryla-
tion of the retinoblastoma protein (pRB),
November 3, 2009 ª2009 Elsevier Inc. 361
